نتایج جستجو برای: pomalidomide

تعداد نتایج: 497  

2018
Konstantinos Dimopoulos Alexandra Søgaard Helbo Helga Fibiger Munch-Petersen Lene Sjö Jesper Christensen Lasse Sommer Kristensen Fazila Asmar Niels Emil Ulrich Hermansen Casey O'Connel Peter Gimsing Gangning Liang Kirsten Grønbaek

Thalidomide and its derivatives, lenalidomide and pomalidomide (also known as IMiDs), have significantly changed the treatment landscape of multiple myeloma, and the recent discovery of cereblon (CRBN) as their direct biological target has led to a deeper understanding of their complex mechanism of action. In an effort to comprehend the precise mechanisms behind the development of IMiD resistan...

Journal: :The Lancet. Oncology 2013
Jesus San Miguel Katja Weisel Philippe Moreau Martha Lacy Kevin Song Michel Delforge Lionel Karlin Hartmut Goldschmidt Anne Banos Albert Oriol Adrian Alegre Christine Chen Michele Cavo Laurent Garderet Valentina Ivanova Joaquin Martinez-Lopez Andrew Belch Antonio Palumbo Stephen Schey Pieter Sonneveld Xin Yu Lars Sternas Christian Jacques Mohamed Zaki Meletios Dimopoulos

BACKGROUND Few effective treatments exist for patients with refractory or relapsed and refractory multiple myeloma not responding to treatment with bortezomib and lenalidomide. Pomalidomide alone has shown limited efficacy in patients with relapsed multiple myeloma, but synergistic effects have been noted when combined with dexamethasone. We compared the efficacy and safety of pomalidomide plus...

Journal: :Blood 2017
Giovanni Palladini Paolo Milani Andrea Foli Marco Basset Francesca Russo Stefano Perlini Giampaolo Merlini

Immunomodulatory drugs are active agents in light-chain (AL) amyloidosis. However, previous studies could not show a survival advantage for patients with AL amyloidosis responding to salvage treatment with pomalidomide. In this phase 2 trial, we assessed the safety and efficacy of pomalidomide and dexamethasone (PDex) in patients with AL amyloidosis who were previously exposed to bortezomib, al...

Journal: :Blood 2013
Alessandra Larocca Vittorio Montefusco Sara Bringhen Davide Rossi Claudia Crippa Roberto Mina Monica Galli Magda Marcatti Giacinto La Verde Nicola Giuliani Valeria Magarotto Tommasina Guglielmelli Delia Rota-Scalabrini Paola Omedé Alberto Santagostino Ileana Baldi Angelo Michele Carella Mario Boccadoro Paolo Corradini Antonio Palumbo

We performed a phase 1/2 trial to determine the maximum tolerated dose (MTD) of pomalidomide and to explore its efficacy when combined with cyclophosphamide-prednisone in relapsed/refractory myeloma patients. Pomalidomide was given at 1 to 2.5 mg/d, cyclophosphamide at 50 mg every other day, prednisone at 50 mg every other day, for 6 28-day cycles, followed by pomalidomide-prednisone maintenanc...

Journal: :Journal of Flow Chemistry 2022

The immunomodulatory drugs (IMiDs) thalidomide, pomalidomide, and lenalidomide are widely used to treat multiple myeloma. permanent need of IMiDs analogues in clinical screening practice has created the demand find a reliable robust method for their preparation. To reach this goal, use flow chemistry is quite appealing, allowing safe operation, an excellent reproducibility efficient process. He...

2017
Runzhe Chen Yujie Wang Chengxin Luan Chong Gao Xiaoping Zhang Baoan Chen

In this work, we aim to further analyze the effect of pomalidomide for relapsed and/or refractory multiple myeloma (RRMM). A systematic literature search of PubMed, MEDLINE and EMBASE was conducted on September 20, 2016. Pooled effect size (ES) with corresponding 95% confidence intervals (CIs) were calculated using random-effects model. STATA software (version 12.0; Stata Corporation; College S...

2017
Jaeyeun Lee John G. Kosowicz Richard F. Ambinder

Kaposi sarcoma (KS) is a debilitating, disfiguring and often fatal disease. The tumor is always associated with Kaposi sarcoma herpesvirus (KSHV, also known as HHV8) [1]. It is often, perhaps always, associated with immune deficiency. In transplant recipients KS is associated with pharmacologic immunosuppression, while in HIV patients KS is associated with low CD4 T cell counts. Improvement in ...

2013
A A Chanan-Khan A Swaika A Paulus S K Kumar J R Mikhael S V Rajkumar A Dispenzieri M Q Lacy

In this report, we provide a comprehensive review on the preclinical and clinical investigations conducted in development of the next-generation immunomodulatory drug (IMiD) pomalidomide for the treatment of relapsed/refractory multiple myeloma (MM). We consulted PubMed, MEDLINE, ASH, ASCO annual symposium abstracts and http://clinicaltrials.gov/ for the purpose of this literature review. Twent...

Journal: :Blood 2013
Xavier Leleu Michel Attal Bertrand Arnulf Philippe Moreau Catherine Traulle Gerald Marit Claire Mathiot Marie Odile Petillon Margaret Macro Murielle Roussel Brigitte Pegourie Brigitte Kolb Anne Marie Stoppa Bernadette Hennache Sabine Bréchignac Nathalie Meuleman Beatrice Thielemans Laurent Garderet Bruno Royer Cyrille Hulin Lotfi Benboubker Olivier Decaux Martine Escoffre-Barbe Mauricette Michallet Denis Caillot Jean Paul Fermand Hervé Avet-Loiseau Thierry Facon

The combination of pomalidomide and dexamethasone can be safely administered to patients with multiple myeloma (MM) and has significant efficacy, although the optimal regimen remains to be determined. Patients with MM whose disease progressed after multiple lines of therapy have limited treatment options. We designed a multicenter, phase 2 randomized study assessing two different dose regimens ...

2011
Robert J. Amato L. Michael Glode Jeremy Podolnick Robert Knight David Crawford

BACKGROUND Pomalidomide is a distinct immunomodulatory agent that also displays anti-proliferative and proapoptotic activity. The purpose of this study was to assess the efficacy and safety of pomalidomide for the treatment of chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (CRPC). METHODS Pomalidomide was administered orally in doses of 1 or 2 mg/day without ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید